Extended Data Figure 10. In vivo effects of BET bromodomain inhibition in VCaP xenograft model.

a, VCaP cells were implanted subcutaneously in mice and grown until tumors reached the size of approximately 100mm³. Xenografted mice were randomized and then received vehicle, 50mg/kg JQ1 or 10mg/kg MDV3100 5 days/week as indicated. Caliper measurements were taken bi-weekly. Individual tumor volume from different treatment groups at the end of the experiments with p-values is shown. b, MDV3100 treatment leads to spontaneous metastasis. Mice bearing VCaP xenografts (subcutaneously engrafted) treated with vehicle (n=6) or MDV3100 (n=6) were assessed for spontaneous metastasis to the femur (bone marrow) and soft tissues such as liver and spleen. Genomic DNA isolated from these sites was analyzed for metastasized cells by measuring human ALU sequence (by Alu-QPCR). MDV3100-treated mice displayed spontaneous metastasis to femur and liver. Spleen did not show presence of human ALU sequences. c as in a, for mice bearing VCaP xenografts treated with vehicle (n = 6), JQ1 (n = 6) or MDV3100 (n = 6). MDV3100-treated but not JQ1-treated mice displayed metastasis to femur and liver. d, JQ1 or MDV3100 treatment does not affect animal weight. Mice from VCaP cell xenograft experiments treated with vehicle, 10mg/kg MDV3100 or 50mg/kg JQ1 were weighed at the time of caliper measurements. e, Individual tumor volume for vehicle or JQ1-treated VCaP mouse xenograft (for data shown in Figure 4c). Mean ± S.E. is plotted. Statistical significance by two-tailed Student's t-test.